Cart
sales@molnova.com
PD-1/PD-L1-IN-9
CAS No. 2628506-54-5
PD-1/PD-L1-IN-9( —— )
Catalog No. M37646 CAS No. 2628506-54-5
PD-1/PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1/PD-L1 interaction. It enhances the immune cells' ability to kill tumor cells and demonstrates significant antitumor activity in vivo in a CT26 mouse model.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 84 | Get Quote |
|
| 5MG | 129 | Get Quote |
|
| 10MG | 188 | Get Quote |
|
| 25MG | 305 | Get Quote |
|
| 50MG | 415 | Get Quote |
|
| 100MG | 536 | Get Quote |
|
| 500MG | 1062 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePD-1/PD-L1-IN-9
-
NoteResearch use only, not for human use.
-
Brief DescriptionPD-1/PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1/PD-L1 interaction. It enhances the immune cells' ability to kill tumor cells and demonstrates significant antitumor activity in vivo in a CT26 mouse model.
-
DescriptionPD-1/PD-L1-IN-9 is a potent and orally active inhibitor of PD-1/PD-L1 interaction, with an IC50 of 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 also exhibits significant in vivo antitumor activity in a CT26 mouse model.
-
In Vitro——
-
In VivoAnimal Model:Male BALB/c mice (5-6 weeks) were inoculated CT26 cells Dosage:40 mg/kg, 80 mg/kg Administration:Oral gavage; once daily, for 2 weeks Result:Significantly decreased the final tumor weight, with TGI values of 60 and 67% at the dose of 40 and 80 mg/kg, respectively.Animal Model:Pharmacokinetic analysis in sprague-Dawley (SD) ratsDosage:3 mg/kg and 25 mg/kg Administration:Intravenous injection or oral gavage.
-
Synonyms——
-
PathwayImmunology/Inflammation
-
TargetPD-1/PD-L1
-
RecptorPD-1/PD-L1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2628506-54-5
-
Formula Weight348.44
-
Molecular FormulaC22H24N2O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (286.99 mM; Ultrasonic )
-
SMILESCOc1nc(ccc1CNCCO)-c1cccc(c1C)-c1ccccc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Wang T, et, al. Novel Biphenyl Pyridines as Potent Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction. J Med Chem. 2021 May 30.?
molnova catalog
related products
-
Sintilimab
Sintilimab (IBI308) is a humanized IgG4 monoclonal antibody with significant anti-tumor activity that restores endogenous anti-tumor T-cell responses by binding to PD-1 and thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2).
-
Spartalizumab
Spartalizumab (PDR001) is a humanized immunoglobulin G4 monoclonal antibody that selectively binds to PD-1 at low concentrations, exhibiting high activity.
-
(D)-PPA 1
PD-1/PD-L1 interaction inhibitor. Binds to PD-L1 (Kd = 0.51 μM). Inhibits interaction at 1 mg/mL in flow cytometry. Inhibits tumor growth and prolongs survival time of mice in vivo.
